Prestige Brands nabs J&J's Dramamine pills; EMA confirms somatropin safety review;

@FiercePharma: Embattled J&J plant cited again by FDA. News  | Follow @FiercePharma

> Prestige Brands said it will buy the Dramamine pills business in the U.S. from Johnson & Johnson's beleaguered McNeil unit for $76 million in cash. Story

> The European Medicines Agency confirmed it is reviewing the safety of the growth hormone somatropin, the key ingredient in medicines made by Pfizer and Roche, but stressed that there is no immediate concern as long as the drugs are used as approved. Report

> The Department of Justice decided not to step into a whistleblower suit against Gilead Sciences involving a subsidiary's marketing of the drug Ranexa. News

> A group of activist investors and patients have filed a lawsuit against the Centers for Medicare & Medicaid Services to force the agency to disclose its reasons for conducting a so-called National Coverage Analysis for the controversial Provenge prostate cancer vaccine. Report

> The U.K. government has begun a consultation process for its plans to change the way medicines are priced. Article

> A sprawling review of GlaxoSmithKline's advertising business on U.S. pharmaceutical brands is down to a shortlist of 20 agency networks. Article

> Congress has voted unanimously to create, for the first time, a national plan to combat Alzheimer's disease with the same intensity as the attacks on AIDS and cancer. Item

Biotech News

@FierceBiotech: Struggling ARYx terminates staff, vows to get back on track. Article | Follow @FierceBiotech

 @JohnCFierce: Impax will get $11.5M upfront and up to $175M in milestones from GSK on Parkinson's drug pact. Story | Follow @JohnCFierce

> AZ's blockbuster Brilinta runs into FDA roadblock. News 

> InterMune's shares rise as CHMP backs pirfenidone. Report

> Sanofi and Merck KGaA join forces on combo cancer drugs. Article

> NovImmune raises $20.7M for mAb work. Story

And Finally... Giving the correct dose of an over-the-counter pediatric medicine is critical, but the package labeling and dosing information can be virtually incomprehensible. And an overdose can be deadly. Story

Suggested Articles

At one point, Novartis even offered up $90 apiece for the inclisiran developer but would later say even $85 was too much, a securities filing shows.

Sanofi spent months hyping its Tuesday investor event, and new CEO Paul Hudson certainly laid out a different vision for the drugmaker at the confab.

After more than 10 years as partners, Sanofi and Regeneron are splitting up their deal to comarket PCSK9 med Praluent and immunology drug Kevzara.